Ascentage

Langsung dari ASCO 2024 | Ascentage Pharma Merilis Data Terbaru Inhibitor FAK/ALK/ROS1 APG-2449 pada Pasien NSCLC oleh Investing.com

oleh

Ascentage Pharma continues to push the boundaries of cancer treatment with their innovative drug candidate, APG-2449, a FAK/ALK/ROS1 tyrosine kinase inhibitor. The latest data presented at the ASCO Annual Meeting demonstrates promising efficacy in patients with non-small-cell lung cancer (NSCLC), particularly in those who are resistant to second-generation ALK inhibitors. Biomarker analysis showed correlations between … Baca Selengkapnya

AACR 2024 | Ascentage Pharma Mempersembahkan Hasil dari Tiga Studi di Pertemuan Tahunan Asosiasi Kanker Amerika 2024 oleh Investing.com

oleh

At the 2024 American Association of Cancer Research Annual Meeting (AACR 2024), Ascentage Pharma (6855.HK) made a significant announcement regarding the latest results from three preclinical studies of their novel drug candidates. The studies focused on olverembatinib, MDM2-p53 inhibitor alrizomadlin (R&D Code: APG-115), FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, and embryonic ectoderm development (EED) inhibitor APG-5918. … Baca Selengkapnya